As autonomous AI agents evolve from conversational assistants into true scientific collaborators, the pharmaceutical industry is entering the next chapter of its AI transformation, one in which ...

CAMBRIDGE, Mass., September 17, 2026 — Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the ...

Research published in the Journal of Medicinal Chemistry showcases a novel PROTAC series from Insilico Medicine UAE, advancing local research in targeted protein degradation Insilico Medicine AI R&D ...

FDA Fast Track- and Orphan Drug-designated program reflects Insilico’s strategy to advance AI-designed medicines against difficult-to-treat, age-associated diseases CAMBRIDGE, Mass. — September 22, ...

A cross-validation score depends heavily on how the data is split, not just on the model. Two pipelines with the same model and the same descriptors can report different cross-validation (CV) metrics ...

Cambridge, MA, July 2, 2026 — Insilico Medicine (“Insilico” HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to ...

Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the ...

The GENESIS-IPF Phase IIa study showed manageable safety and tolerability, with the 60 mg once-daily arm demonstrating mean forced vital capacity improvement of +98.4 mL at 12 weeks CAMBRIDGE, Mass., ...

Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received ...

CAMBRIDGE, Mass., Sep 10, 2026 — Insilico Medicine (“Insilico,” HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with ...

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage ...

CAMBRIDGE, Mass. — Monday, September 7, 2026 (5AM EST) — Insilico Medicine (“Insilico”), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the ...